XOMA (XOMAP) Competitors $25.62 -0.29 (-1.12%) (As of 12/11/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFinancialsHeadlinesSEC FilingsShort InterestTrends XOMAP vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying XOMA stock or one of its competitors? The main competitors of XOMA include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. XOMA vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and XOMA (NASDAQ:XOMAP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking. Is ATNFW or XOMAP more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A XOMA N/A N/A N/A Does the MarketBeat Community believe in ATNFW or XOMAP? 180 Life Sciences and XOMA both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AXOMAN/AN/A Does the media favor ATNFW or XOMAP? In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.87 beat XOMA's score of 0.93 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive XOMA Positive Which has better valuation and earnings, ATNFW or XOMAP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AXOMA$9.71MN/AN/AN/AN/A Summary180 Life Sciences and XOMA tied by winning 1 of the 2 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMAP vs. The Competition Export to ExcelMetricXOMABiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$166.88M$5.26B$9.28BDividend Yield9.29%3.50%5.12%3.95%P/E RatioN/A326.32134.7817.62Price / SalesN/A16,420.601,262.01141.14Price / CashN/A11.6735.5735.65Price / BookN/A7.344.824.95Net IncomeN/A-$18.37M$119.04M$225.72M7 Day Performance-1.14%0.49%1.50%1.70%1 Month Performance-0.21%11.60%-0.56%5.09%1 Year Performance13.74%35.96%33.02%29.01% XOMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAPXOMAN/A$25.63-1.1%N/A+12.1%$0.00$9.71M0.0013ATNFW180 Life SciencesN/A$0.01-16.5%N/A+21.3%$0.00N/A0.007Gap DownSXTPW60 Degrees PharmaceuticalsN/A$0.02+0.7%N/A-22.6%$0.00$502,409.000.002Gap UpDRTSWAlpha Tau MedicalN/A$0.24+4.1%N/A+18.4%$0.00N/A0.0080Positive NewsGap DownWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-6.0%N/A-76.2%$0.00N/A0.0059Short Interest ↑BCTXWBriaCell TherapeuticsN/A$0.50+14.4%N/A-68.8%$0.00N/A0.008Short Interest ↑Positive NewsGap DownHigh Trading VolumeCDIOWCardio DiagnosticsN/A$0.05-6.2%N/A+34.9%$0.00$35,688.000.007Short Interest ↓High Trading VolumeCTCXWCarmellN/A$0.04+4.9%N/AN/A$0.00$32,839.000.009Gap UpCELUWCelularityN/A$0.02+31.2%N/A+75.6%$0.00$42.69M0.00220Gap UpCEROWCERo TherapeuticsN/A$0.01+30.6%N/AN/A$0.00N/A0.008Short Interest ↑Gap UpHigh Trading Volume Related Companies and Tools Related Companies 180 Life Sciences Alternatives 60 Degrees Pharmaceuticals Alternatives Alpha Tau Medical Alternatives Anew Medical Alternatives Apollomics Alternatives BriaCell Therapeutics Alternatives Cardio Diagnostics Alternatives Carmell Alternatives Celularity Alternatives CERo Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XOMAP) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredWant to Start Investing? It’s Easier Than You Think!Many people think you need a lot of money to start investing—but that’s simply not true. Andy Tanner, Rich ...The Cashflow Academy | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
